Loading...
XSHE
300347
Market cap6.91bUSD
Jul 10, Last price  
57.88CNY
1D
0.52%
1Q
28.79%
Jan 2017
114.29%
IPO
204.63%
Name

Hangzhou Tigermed Consulting Co Ltd

Chart & Performance

D1W1MN
P/E
160.75
P/S
9.86
EPS
0.36
Div Yield, %
0.98%
Shrs. gr., 5y
2.97%
Rev. gr., 5y
18.69%
Revenues
6.60b
-10.58%
62,792,911122,844,075193,263,834254,315,147336,518,889624,561,658956,997,6821,174,538,2031,687,033,4552,300,659,7062,803,309,2873,192,278,5045,213,538,0547,085,471,4687,384,039,4606,603,120,162
Net income
405m
-79.99%
7,801,02231,709,27247,791,76167,748,51294,056,536125,496,309156,277,965140,651,982301,013,932472,183,931841,634,8231,749,774,7812,874,163,0202,006,552,0352,024,849,989405,143,491
CFO
1.10b
-4.64%
21,948,30026,585,75338,691,55014,982,51977,099,58643,660,896185,732,093191,910,992314,970,861522,242,718527,557,935998,675,0961,423,796,2501,357,500,8921,150,437,9421,097,001,903
Dividend
Jul 12, 20240.568 CNY/sh

Profile

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
URL
https://www.tigermedgrp.com/
IPO date
Aug 17, 2012
Employees
9,455
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,603,120
-10.58%
7,384,039
4.21%
7,085,471
35.91%
Cost of revenue
4,948,746
5,103,788
4,917,578
Unusual Expense (Income)
NOPBT
1,654,374
2,280,251
2,167,894
NOPBT Margin
25.05%
30.88%
30.60%
Operating Taxes
216,630
338,606
313,652
Tax Rate
13.09%
14.85%
14.47%
NOPAT
1,437,744
1,941,645
1,854,242
Net income
405,143
-79.99%
2,024,850
0.91%
2,006,552
-30.19%
Dividends
(589,867)
Dividend yield
1.93%
Proceeds from repurchase of equity
(29,850)
BB yield
0.10%
Debt
Debt current
1,912,017
1,969,694
2,067,697
Long-term debt
1,122,283
1,280,441
1,222,592
Deferred revenue
17,136
14,786
Other long-term liabilities
2,785
231,112
73,117
Net debt
(12,559,644)
(17,393,095)
(16,362,999)
Cash flow
Cash from operating activities
1,097,002
1,150,438
1,357,501
CAPEX
Cash from investing activities
(1,534,225)
Cash from financing activities
(7,806)
809,254
FCF
537,996
1,464,621
737,471
Balance
Cash
2,130,198
7,462,130
7,883,086
Long term investments
13,463,746
13,181,099
11,770,203
Excess cash
15,263,788
20,274,027
19,299,015
Stockholders' equity
12,947,422
13,074,000
11,306,312
Invested Capital
13,771,962
14,437,699
14,066,198
ROIC
10.19%
13.62%
13.96%
ROCE
6.15%
8.29%
8.47%
EV
Common stock shares outstanding
862,007
864,949
864,893
Price
30.80
-12.87%
35.35
-60.81%
90.20
-8.89%
Market cap
26,549,829
-13.17%
30,575,932
-60.81%
78,013,357
-9.52%
EV
17,384,011
16,609,624
64,748,366
EBITDA
1,978,515
2,585,937
2,432,639
EV/EBITDA
8.79
6.42
26.62
Interest
141,235
119,897
83,179
Interest/NOPBT
8.54%
5.26%
3.84%